{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:01:38Z","timestamp":1788238898930,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating anemia in cancer patients, the number of studies reporting the efficacy of iron replacement in cancer patients is limited. In this study, the efficacy and safety of iron carboxymaltose, a parenteral iron treatment option, in the treatment of anemia, were examined retrospectively. A total of 1102 adult patients who received IV ferric carboxymaltose treatment at Hacettepe Oncology Hospital between 2014 and 2020 were included. The mean hemoglobin change observed at the end of the 12th week was 1.8 g\/dL, and the rate of patients with an increase in hemoglobin of 1 g\/dL or more was 72.1%. It was observed that the treatment demonstrated effectiveness in patients receiving active cancer treatment in all tumor types. The treatment was generally safe, and no grade 3\u20135 side effects were observed in the patients included in the study. According to one of the most extensive series published in the literature, iron carboxymaltose is an efficient and safe alternative for cancer patients with iron-deficiency anemia.<\/jats:p>","DOI":"10.3390\/curroncol30110703","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:05:07Z","timestamp":1698890707000},"page":"9689-9700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia"],"prefix":"10.3390","volume":"30","author":[{"given":"Burak Yasin","family":"Akta\u015f","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"},{"name":"Department of Medical Oncology, Guy\u2019s and Saint Thomas\u2019 NHS Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine B\u00fc\u015fra","family":"Ata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"\u00c7e\u015fmeci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Yahya","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Co\u015fkunp\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u011fmur","family":"Tahillio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrkan","family":"G\u00fcner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer","family":"Ar\u0131k","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyran","family":"Kertmen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-9078","authenticated-orcid":false,"given":"\u00d6mer","family":"Dizdar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015euayib","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe Cancer Institute, Ankara 06230, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijrobp.2005.04.049","article-title":"Anemia, tumor hypoxemia, and the cancer patient","volume":"63","author":"Varlotto","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1007\/s00520-016-3258-3","article-title":"The effect of chemotherapy-induced anemia on dose reduction and dose delay","volume":"24","author":"Family","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/oncolo\/oyac005","article-title":"Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study)","volume":"27","author":"Gluszak","year":"2022","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2018.01294","article-title":"Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach","volume":"9","author":"Madeddu","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00520-016-3511-9","article-title":"Estimating prevalence of functional iron deficiency anaemia in advanced cancer","volume":"25","author":"Neoh","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s12094-013-1155-5","article-title":"Iron deficiency in patients with solid tumours: Prevalence and management in clinical practice","volume":"16","author":"Casas","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.bcp.2008.12.018","article-title":"Linking anemia to inflammation and cancer: The crucial role of TNF\u03b1","volume":"77","author":"Buck","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hoenemann, C., Ostendorf, N., Zarbock, A., Doll, D., Hagemann, O., Zimmermann, M., and Luedi, M. (2021). Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron Deficiency and Anemia Diagnostics in Patient Blood Management. A Narrative Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184250"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2015-03-636407","article-title":"Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia","volume":"125","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/bjs.10328","article-title":"Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer","volume":"104","author":"Keeler","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/annonc\/mds338","article-title":"Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia","volume":"24","author":"Steinmetz","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jang, J.H., Kim, Y., Park, S., Kim, K., Kim, S.J., Kim, W.S., Jung, C.W., Lee, J., and Lee, S.H. (2020). Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003091"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00520-015-2728-3","article-title":"Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France","volume":"24","author":"Toledano","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_22","first-page":"654","article-title":"The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study","volume":"30","author":"Verhaeghe","year":"2017","journal-title":"Ann. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ajh.26376","article-title":"Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD)","volume":"96","author":"Makharadze","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1758835920953292","DOI":"10.1177\/1758835920953292","article-title":"Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents","volume":"12","author":"Saadeh","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S2352-3026(22)00402-1","article-title":"Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): A multicentre, open-label, randomised, controlled trial","volume":"10","author":"Talboom","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_26","first-page":"939","article-title":"Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: A pilot study","volume":"7","author":"Abbasi","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_27","first-page":"310","article-title":"Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: A randomised controlled trial","volume":"20","author":"Vives","year":"2022","journal-title":"Blood Transfus."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"647930","DOI":"10.1155\/2015\/647930","article-title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice","volume":"2015","author":"Bach","year":"2015","journal-title":"Anemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/hematology.2019000034","article-title":"Management of iron deficiency","volume":"2019","author":"Ning","year":"2019","journal-title":"Hematology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00384-015-2461-x","article-title":"Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia","volume":"31","author":"Calleja","year":"2016","journal-title":"Int. J. Color. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20410","DOI":"10.1038\/s41598-019-56999-3","article-title":"Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: An effective, safe and cost- sparing alternative to blood transfusion","volume":"9","author":"Marinho","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2257.2006.00812.x","article-title":"Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states","volume":"28","author":"Brugnara","year":"2006","journal-title":"Clin. Lab. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcmd.2010.07.013","article-title":"Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI)","volume":"45","author":"Sasu","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bcmd.2016.05.006","article-title":"Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose","volume":"59","author":"Drakou","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2013-10-512624","article-title":"How I treat unexplained refractory iron deficiency anemia","volume":"123","author":"Hershko","year":"2014","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CNP71125","article-title":"Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients","volume":"71","author":"Grimmelt","year":"2009","journal-title":"Clin. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/17843286.2022.2153465","article-title":"Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: A retrospective cohort study","volume":"78","author":"Decruyenaere","year":"2023","journal-title":"Acta Clin. Belg."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:52Z","timestamp":1760130952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["curroncol30110703"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30110703","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}